Insulin, insulin analogues and diabetic retinopathy

References

• Aguilar E, Friedlander M, Gariano R F. Endothelial proliferation in diabetic retinal microaneurysms. Arch Ophthalmol 2003; 121: 740–741
   PubMed Web of Science ®Google Scholar
• Antonetti D A, Barber A J, Bronson S K, Freeman W M, Gardner T W, Jefferson L S, Kester M, Kimball S R, Krady J K, Lanoue K F, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55: 2401–2411
   PubMed Web of Science ®Google Scholar
• Ashton N. Pathogenesis of diabetic retinopathy. Diabetic Retinopathy, H L Little, R L Jack, A Patz, P H Forsham. Thieme-Stratton Inc, New York 1983; 85–106
   Google Scholar
• Bereket A, Lang C H, Wilson T A. Alterations in the growth homone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999; 31: 172–181
   PubMed Web of Science ®Google Scholar
• Berger M R, Fink M, Feichter G E, Janetschek P. Effects of diazoxide-induced reversible diabetes on chemically induced autochthonus mammary carcinomas in Sprague-Dawley rats. Int J Cancer 1985; 35: 395–401
   PubMed Web of Science ®Google Scholar
• Bergman P B, Moravski C J, Edmondson S R, Russo V C, Bach L A, Wilkinson-Berka J L, Werther G A. Expression of the IGF system in normal and diabetic transgenic (mRen-2)27 rat eye. Invest Ophthalmol Vis Sci 2005; 46: 2708–2715
   PubMed Web of Science ®Google Scholar
• Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen K F, Sandvik L, the Oslo Study Group. Effect of intensified insulin treatment on various lesions of diabetic retinopathy. Am J Ophthalmol 1985; 100: 644–653
   PubMed Web of Science ®Google Scholar
• Buchbinder A, Miodovnik M, McElvy S, Rosenn B, Kranias G, Khoury J, Siddiqi T A. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy. Am J Obstet Gynecol 2000; 183: 1162–1165
   PubMed Web of Science ®Google Scholar
• Cassar J, Kohner E M, Hamilton A M, Gordon H, Joplin G F. Diabetic retinopathy and pregnancy. Diabetologia 1978; 15: 105–111
   PubMed Web of Science ®Google Scholar
• Chantelau E. Evidence that up-regulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725–730
   PubMed Web of Science ®Google Scholar
• Chantelau E, Volaco A, Meyer-Schwickerath R. New insights into the pathogenesis of diabetic retinopathy—hormonal rather than metabolic factors are important. VASA 2004; 33: 205–210, (Erratum: VASA 2005;34:66)
   PubMedGoogle Scholar
• Chao J R, Lai M Y, Azen S P, Klein R, Varma R, the Los Angeles Eye Study Group. Retinopathy in persons without diabetes: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2007; 48: 4019–4025
   PubMed Web of Science ®Google Scholar
• Chisalita S I, Arnqvist H J. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004; 286: E896–E901
   PubMed Web of Science ®Google Scholar
• Chisalita S I, Nitert M D, Arnqvist H J. Characterisation of receptors for IGF-1 and insulin; evidence for hybrid insulin/IGF-1 receptor in human coronary artery endothelial cells. Growth Horm IGF Res 2006; 16: 258–266
   PubMed Web of Science ®Google Scholar
• Danis R P, Bingaman D P. Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 1997; 104: 1661–169
   PubMed Web of Science ®Google Scholar
• Davis M D, Beck R W, Home P D, Sandow J, Ferris F L. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. Exp Clin Endocrinol Diabetes 2007; 115: 240–243, (Erratum in: Exp Clin Endocrinol Diabetes 2007;115:473)
   PubMed Web of Science ®Google Scholar
• De Bosch B J, Baur E, Deo B K, Hiraoka M, Kumagai A K. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. J Neurochem 2001; 77: 1157–1167
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874–886, (Erratum: Arch Ophthalmol 1998;116:1469)
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995a; 44: 968–983
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive vs. conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995b; 102: 647–661
   Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The DCCT Arch Ophthalmol 1995c; 113: 36–51
   PubMed Web of Science ®Google Scholar
• Eckel J. Insulin analogs revisited. Curr Med Chem Immunology, Endoc & Metab Agents 2005; 5: 475–484
   Google Scholar
• Ekström K, Salemy J, Zachrisson I, Carlsson-Skwirut C, Örtqvist E, Bang P. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type-1 diabetes. Diabetes Care 2007; 30: 1357–1363
   PubMed Web of Science ®Google Scholar
• EMEA (European Medicines Agency). 2004a. EPARs for authorised medicinal product for human use-Actrapid, www.emea.europa.eu/humandocs/Humans/EPAR/actrapid/actrapid.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2004b. EPARs for authorised medicinal product for human use-Levemir, www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2004c. EPARs for authorised medicinal product for human use-NovoRapid, www.emea.europa.eu/humandocs/Humans/EPAR/novorapid/novorapid.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2005a. EPARs for authorised medicinal product for human use-Apidra, www.emea.europa.eu/humandocs/Humans/EPAR/apidra/apidra.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2005b. EPARs for authorised medicinal product for human use-Humalog, www.emea.europa.eu/humandocs/Humans/EPAR/humalog/humalog.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2005c. EPARs for authorised medicinal product for human use-Insuman, www.emea.europa.eu/humandocs/Humans/EPAR/insuman/insuman.htm (accessed September 2007).
   Google Scholar
• EMEA (European Medicines Agency). 2005d. EPARs for authorised medicinal product for human use-Lantus, www.emea.europa.eu/humandocs/Humans/EPAR/lantus/lantus.htm (accessed September 2007).
   Google Scholar
• Fischer F. Klinische Studie zur Retinitis diabetica proliferans (in German). Graefes Archiv für Ophthalmologie 1955; 156: 552–560
   PubMedGoogle Scholar
• Frankfurter Allgemeine Zeitung. 2007. Aktie von Novo Nordisk eignet sich als defensives Investment, 12 September 2007.
   Google Scholar
• Garg S K, Pennington M, Gottlieb P, Anderson J, Jenning K, Robinson J. Comparison of maternal and fetal outcome between human regular and Humalog® insulin treated pregnancies in type-1 diabetes (Abstract). Diabetes 1999; 48/Suppl.1: A61
   Web of Science ®Google Scholar
• Gariano R F, Gardner T W. Retinal angiogenesis in development and disease. Nature 2005; 438: 960–966
   PubMed Web of Science ®Google Scholar
• Grant M B, Mames R N, Fitzgerald C, Ellis E A, Aboufriekha M, Guy J. Insulin-like growth factor 1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282–291
   PubMed Web of Science ®Google Scholar
• Hammes H P. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005; 37/Suppl.1: 39–43
   Google Scholar
• Hedman C A, Orre-Pettersson A C, Lindström T, Arnqvist H J. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-1 and IGFBP-1 in type-1 diabetes. Clin Endocrinol 2001; 55: 107–112
   PubMed Web of Science ®Google Scholar
• Hellström A, Perruzzi C, Ju M, Engstrom E, Hard A L, Liu J L, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, et al. Low IGF-1 suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001; 98: 5804–5808
   PubMed Web of Science ®Google Scholar
• Hennige A M, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Häring H U. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274–1282
   PubMed Web of Science ®Google Scholar
• Hennige A M, Strack V, Metzinger E, Seipke G, Häring HU,Kellerer M. Effects of new insulin analogues HMR1964(insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 2005a; 48: 1891–1897
   PubMed Web of Science ®Google Scholar
• Hennige A M, Lehmann R, Weigert C, Moeschel K, Schäuble M, Metzinger E, Lammers R, Häring H U. Insulin Glulisine. Insulin receptor signaling characteristics in vivo. Diabetes 2005b; 54: 361–366
   Google Scholar
• Home P D, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type-1 diabetes. Diabetes Metab Rev Res 2005; 21: 545–553
   PubMed Web of Science ®Google Scholar
• Hussain M A, Studer K, Messmer E P, Froesch E R. Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes 1995; 44: 1209–1212
   PubMed Web of Science ®Google Scholar
• Janssen J AMJL, Lamberts S WJ. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 2000; 52: 1–9
   PubMed Web of Science ®Google Scholar
• Joussen A M, Fauser S, Krohne T U, Lemmen K D, Lang G E, Kirchhof B. Diabetic retinopathy. Pathophysiology and therapy of hypoxia-induced inflammation (in German). Ophthalmologe 2003; 100: 363–370
   Google Scholar
• Jovanovic L, Pettitt D J. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care 2007; 30/Suppl.2: S220–S224
   Web of Science ®Google Scholar
• Kern T S, Miller C M, Du Y, Zheng L, Mohr S, Ball S L, Kim M, Jamison J A, Bingaman D P. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56: 373–379
   PubMed Web of Science ®Google Scholar
• Kitamei H, Yokoi M, Kase M, Ohno S. Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome. Graefe's Arch Clin Exp Ophthalmol 2005; 243: 715–717
   PubMed Web of Science ®Google Scholar
• Kitzmiller J L, Main E, Ward B, Theiss T, Peterson D L. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy (Letter). Diabetes Care 1999; 22: 874–876
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Puro D G. Loss of insulin-mediated vasoprotection: early effect of diabetes on pericyte-containing microvessels of the retina. Invest Ophthalmol Vis Sci 2007; 48: 2350–2355
   PubMed Web of Science ®Google Scholar
• Kohner E M, Patel V, Rassam S MB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44: 603–607
   PubMed Web of Science ®Google Scholar
• Kondo T, Vicent D, Suzuma K, Yanagisawa M, King G L, Holzenberger M, Kahn R C. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protect against retinal neo-vascularisation. J Clin Invest 2003; 111: 1835–1842
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005
   PubMed Web of Science ®Google Scholar
• Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity). The personal experience 1958–2003. J Clin Endocrinol Metab 2004; 89: 1031–1044
   PubMed Web of Science ®Google Scholar
• Lauritzen T, Frost-Larsen K, Larsen H W, Deckert T, Steno Study Group. Effect of 1 year of near-normal blood glucose levels on diabetic retinopathy in insulin-dependent diabetics. Lancet 1983; i: 200–204
   Google Scholar
• Layton C J, Becker S, Osborne N N. The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2. Molecular Vision 2006; 12: 43–54
   PubMed Web of Science ®Google Scholar
• Leber T. Über die Erkrankungen des Augen bei Diabetes mellitus. Graefes Archiv für Ophthalmologie 1875; 21/III: 206–337
   Google Scholar
• Lee H K, Suh K I, Koh C S, Min H K, Lee J H, Chung H. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy (Letter). Diabetes Care 1988; 11: 441–443
   PubMed Web of Science ®Google Scholar
• Lee P D, Giudice L C, Conover C A, Powell D R. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216: 319–357
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Immonen I, Teramo K A, Kaaja R. Progression of retinopathy during pregnancy in type-1 diabetic women treated with insulin lispro. Diabetes Care 2003; 26: 1193–1198
   PubMed Web of Science ®Google Scholar
• Martin X D, Zenobi P D. Type A syndrome of insulin resistance: anterior chamber anomalies of the eye and effects of insulin-like growth factor-1 on the retina. Ophthalmologica 2001; 215: 117–123
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type-2 diabetes. Horm Metab Res 2003; 35: 189–196
   PubMed Web of Science ®Google Scholar
• Meyer-Schwickerath R, Pfeiffer A, Blum W F, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H. Vitreous levels of the insulin-like growth factorsI and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 1993; 92: 2620–2625
   Google Scholar
• Min Shi, You-Min Feng. Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogues in mouse mammary tumor cells. Biochem Mol Biol Int 1997; 43: 705–711
   PubMedGoogle Scholar
• Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819–825
   PubMed Web of Science ®Google Scholar
• Patel J I, Hykin P G, Cree I A. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol 2006; 90: 697–701
   PubMed Web of Science ®Google Scholar
• Persson B, Swahn M L, Hjertberg R, Hanson U, Nord E, Nordlander E, Hansson L O. Insulin lispro therapy in pregnancies complicated by type-1 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 115–121
   PubMed Web of Science ®Google Scholar
• Peters K, Garg S K, Jackson W E, Mackenzie T, Queen J, Anil S, Chase P. Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH. Abstract. Diabetes 2001; 50/Suppl 2: A443
   Web of Science ®Google Scholar
• Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy. A possible role of blood retina barrier breakdown. Diabetes 1997; 46/Suppl. 2: S26–S30
   Web of Science ®Google Scholar
• Porta M, Townsend C, Clover G M, Nanson M, Alderson A R, McCraw A, Kohner E M. Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 1981; 20: 597–601
   PubMed Web of Science ®Google Scholar
• Poulaki V, Qin W, Joussen A M, Hurlbut P, Wiegand S J, Rudge J, Yancopoulos G D, Adamis A P. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor 1 alpha and VEGF. J Clin Invest 2002; 109: 805–815
   PubMed Web of Science ®Google Scholar
• Poulaki V, Joussen A M, Mitsiades N, Mitsiades C S, Iliaki E F, Adamis A P. Insulin-like growth factor-1 plays a pathogenic role in diabetic retinopathy. Am J Pathol 2004; 165: 457–469
   PubMed Web of Science ®Google Scholar
• Quattrin T, Thrailkill K, Baker L, Kuntze J, Compton P, Martha P, rhIGF-1 Study Group. Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type-1 diabetes mellitus treated with recombinant human insulin-like growth factor-1 and insulin. rhIGF-1 in IDDM Study Group. J Pediatr Endocrinol Metab 2001; 14: 267–277
   PubMed Web of Science ®Google Scholar
• Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. A novel insulin analog with unique properties. Diabetes 2003; 52: 2227–2238
   PubMed Web of Science ®Google Scholar
• Ratner R E, Hirsch I B, Neifing J L, Garg S K, Mecca T E, Wilson C A. Less hypoglycemia with insulin glargine in intensive insulin therapy for type-1 diabetes. US Study Group of Insulin Glargine in Type-1 Diabetes. Diabetes Care 2000; 23: 639–643
   PubMed Web of Science ®Google Scholar
• Reiter C E, Gardner T W. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 2003; 22: 545–562
   PubMed Web of Science ®Google Scholar
• Reiter C E, Wu X, Sandirasegarane L, Nakamura M, Gilbert K A, Singh R S, Fort P E, Antonetti D A, Gardner T W. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006; 55: 1148–1156
   PubMed Web of Science ®Google Scholar
• Renehan A G, Shalet S M. Diabetes, insulin therapy, and colorectal cancer. Br Med J 2005; 330: 551–552
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Park G, Zimmerman J, US Insulin Glargine (HOE 901) Typ-1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type-1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE) Type-1 Diabetes Investigator Group. Diabetes Care 2000; 23: 1137–1142
   PubMed Web of Science ®Google Scholar
• Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004; 113: 1149–1157
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Tsuneki H, Wada T. Comparison of intracellular signaling properties induced by the long-acting insulin analogues glargine and detemir in cultured cells (Abstract). Diabetologia 2007; 50/Suppl.1: S234
   Web of Science ®Google Scholar
• Shaw L C, Grant M B. Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 2004; 5: 199–207
   PubMed Web of Science ®Google Scholar
• Shigetou M, Sagawa T, Ishibashi T, Nakashima N, Umeda F, Nawata H. Exacerbation of diabetic retinopathy following systemic insulin-like growth factor-1. Report of a case. Rinsho Ganka (Jpn J Clin Ophthalmol) 1997; 51: 1251–1255
   Google Scholar
• Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen K G. Treatment with insulin glargine does not suppress serum IGF-1. Diabetic Med 2006; 23: 814–817
   PubMed Web of Science ®Google Scholar
• Slomiany M G, Rosenzweig S A. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1 stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 2006; 318: 666–675
   PubMed Web of Science ®Google Scholar
• Smeeton F J, Shojaee-Moradie F, Jackson N, Jones R H, Umpleby A M, Russel-Jones D. Is insulin detemir hepatoselective when compared to NPH insulin using stable isotope methodology at plasma glucose concentrations of less than 4 mml/l? (Abstract). Diabetologia 2007; 50/Suppl.1: S24
   Web of Science ®Google Scholar
• Smith L EH. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate 2005; 88: 237–244
   PubMedGoogle Scholar
• Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T, Suzuki H, Yamashita K. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726–730
   PubMed Web of Science ®Google Scholar
• Stammberger I, Seipke G, Bartels T. Insulin glulisine—a comprehensive preclinical evaluation. Int J Toxicol 2006; 25: 25–33
   PubMed Web of Science ®Google Scholar
• Suto C, Hori S, Kato S, Muraoka K, Kitano S. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 2006; 124: 38–45
   PubMed Web of Science ®Google Scholar
• The Kroc Collaborative Study Group. Diabetic retinopathy after 2 years of intensified insulin treatment. JAMA 1988; 260: 37–41
   PubMed Web of Science ®Google Scholar
• Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza G L, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 31: 27975–27981
   Google Scholar
• Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouel-Kartmann M N, Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor 1. Mol Endocrinol 2005; 19: 1304–1317
   PubMed Web of Science ®Google Scholar
• Vigneri R, Belfiore A. Insulin and its receptor in growth promotion. Diabetes in the New Millenium, U DiMario, F Leonetti, G Pugliese, P Sbraccia, A Signore. John Wiley & Sons, Ltd, Chichester 2000; 151–160
   Google Scholar